{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:48:17Z","timestamp":1789181297319,"version":"build-2803163510"},"reference-count":149,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Grant-in-Aid for Young Scientists","award":["23\u00a0K15781"],"award-info":[{"award-number":["23\u00a0K15781"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The management of advanced (locally advanced or metastatic) urothelial carcinoma has been revolutionized since pembrolizumab was introduced in 2017. Several prognostic factors for advanced urothelial carcinoma treated with pembrolizumab have been reported, including conventional parameters such as performance status and visceral (especially liver) metastasis, laboratory markers such as the neutrophil-to-lymphocyte ratio, sarcopenia, histological\/genomic markers such as programmed cell death ligand 1 immunohistochemistry and tumor mutational burden, variant histology, immune-related adverse events, concomitant medications in relation to the gut microbiome, primary tumor site (bladder cancer versus upper tract urothelial carcinoma) and history\/combination of radiotherapy. The survival time of advanced urothelial carcinoma has been significantly prolonged (or \u2018doubled\u2019 from 1 to 2\u00a0years) after the advent of pembrolizumab, which will be further improved with novel agents such as avelumab and enfortumab vedotin. This review summarizes the latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the contemporary era of immune checkpoint inhibitors.<\/jats:p>","DOI":"10.1093\/jjco\/hyad172","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T19:58:31Z","timestamp":1702929511000},"page":"254-264","source":"Crossref","is-referenced-by-count":7,"title":["Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-4294","authenticated-orcid":false,"given":"Satoru","family":"Taguchi","sequence":"first","affiliation":[{"name":"The University of Tokyo Department of Urology, Graduate School of Medicine, , Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-2874","authenticated-orcid":false,"given":"Taketo","family":"Kawai","sequence":"additional","affiliation":[{"name":"Teikyo University School of Medicine Department of Urology, , Itabashi-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Teikyo University School of Medicine Department of Urology, , Itabashi-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"The University of Tokyo Department of Urology, Graduate School of Medicine, , Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"2024031106210578400_ref1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0090-4295(80)90067-9","article-title":"Metastases from transitional cell carcinoma of urinary bladder","volume":"16","author":"Babaian","year":"1980","journal-title":"Urology"},{"key":"2024031106210578400_ref2","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"2024031106210578400_ref3","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"2024031106210578400_ref4","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"2024031106210578400_ref5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/02841860802325932","article-title":"Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and\/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy","volume":"48","author":"Jessen","year":"2009","journal-title":"Acta Oncol"},{"key":"2024031106210578400_ref6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jjco\/hyt096","article-title":"Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy","volume":"43","author":"Taguchi","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2024031106210578400_ref7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00345-015-1631-3","article-title":"Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world","volume":"34","author":"Taguchi","year":"2016","journal-title":"World J Urol"},{"key":"2024031106210578400_ref8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/iju.13067","article-title":"Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy","volume":"23","author":"Hsieh","year":"2016","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"KEYNOTE-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2024031106210578400_ref10","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/jjco\/hyab121","article-title":"Current status and future perspectives of immunotherapy against urothelial and kidney cancer","volume":"51","author":"Kobayashi","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2024031106210578400_ref11","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/iju.15101","article-title":"Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: efficacy, safety, and evidence for trial-unfit patients","volume":"30","author":"Ito","year":"2023","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/iju.14601","article-title":"Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: a multicenter retrospective study","volume":"28","author":"Narita","year":"2021","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/CMAR.S348899","article-title":"Significant improvement of prognosis after the advent of immune checkpoint inhibitors in patients with advanced, unresectable, or metastatic urothelial carcinoma: a propensity score matching and inverse probability of treatment weighting analysis on real-world data","volume":"14","author":"Miyake","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2024031106210578400_ref14","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/iju.15014","article-title":"Improved survival in real-world patients with advanced urothelial carcinoma: a multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003\u20132011) and a more recent period (2016\u20132020)","volume":"29","author":"Taguchi","year":"2022","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref15","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2024031106210578400_ref16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2024031106210578400_ref17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00262-020-02709-2","article-title":"Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab","volume":"70","author":"Kijima","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2024031106210578400_ref18","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cas.14762","article-title":"Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci"},{"key":"2024031106210578400_ref19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10147-021-02046-z","article-title":"Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis","volume":"27","author":"Isobe","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"2024031106210578400_ref20","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1038\/s41598-021-95061-z","article-title":"Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study","volume":"11","author":"Taguchi","year":"2021","journal-title":"Sci Rep"},{"key":"2024031106210578400_ref21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2217\/fon.14.172","article-title":"Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?","volume":"11","author":"Buti","year":"2015","journal-title":"Future Oncol"},{"key":"2024031106210578400_ref22","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"2024031106210578400_ref23","first-page":"5","article-title":"Ratio of neutrophil to lymphocyte counts\u2013rapid and simple parameter of systemic inflammation and stress in critically ill","volume":"102","author":"Zahorec","year":"2001","journal-title":"Bratisl Lek Listy"},{"key":"2024031106210578400_ref24","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2024031106210578400_ref25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/iju.12766","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: a multi-institutional study","volume":"22","author":"Taguchi","year":"2015","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref26","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.clgc.2016.10.013","article-title":"Prognostic value of baseline neutrophil-to-lymphocyte ratio in metastatic urothelial carcinoma patients treated with first-line chemotherapy: a large multicenter study","volume":"15","author":"Auvray","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2024031106210578400_ref27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/diagnostics10050310","article-title":"Clinical impact of sarcopenia and inflammatory\/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with Pembrolizumab","volume":"10","author":"Shimizu","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"2024031106210578400_ref28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10147-019-01613-9","article-title":"Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice","volume":"25","author":"Tamura","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"2024031106210578400_ref29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1159\/000508923","article-title":"Low geriatric nutritional risk index as a poor prognostic marker for second-line pembrolizumab treatment in patients with metastatic urothelial carcinoma: a retrospective multicenter analysis","volume":"98","author":"Etani","year":"2020","journal-title":"Oncology"},{"key":"2024031106210578400_ref30","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol Oncol"},{"key":"2024031106210578400_ref31","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.21873\/anticanres.14922","article-title":"Predictive impact of prognostic nutritional index on Pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy","volume":"41","author":"Ishiyama","year":"2021","journal-title":"Anticancer Res"},{"key":"2024031106210578400_ref32","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.21873\/anticanres.14921","article-title":"Blood cell count biomarkers predicting efficacy of pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"41","author":"Kadono","year":"2021","journal-title":"Anticancer Res"},{"key":"2024031106210578400_ref33","doi-asserted-by":"crossref","first-page":"e1398","DOI":"10.1002\/cnr2.1398","article-title":"Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: a retrospective single-center analysis in Japan","volume":"4","author":"Fujiwara","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"2024031106210578400_ref34","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.3390\/cancers13143554","article-title":"Risk classification for overall survival by the neutrophil-lymphocyte ratio and the number of metastatic sites in patients treated with Pembrolizumab-a multicenter collaborative study in Japan","volume":"13","author":"Uchimoto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024031106210578400_ref35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10147-020-01784-w","article-title":"Prognostic value of pre-treatment risk stratification and post-treatment neutrophil\/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma","volume":"26","author":"Yamamoto","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2024031106210578400_ref36","doi-asserted-by":"crossref","first-page":"21199","DOI":"10.1038\/s41598-021-00509-x","article-title":"FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab","volume":"11","author":"Kawashima","year":"2021","journal-title":"Sci Rep"},{"key":"2024031106210578400_ref37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/CAD.0000000000001279","article-title":"Sarcopenia and the rate of change of the neutrophil\/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma","volume":"33","author":"Fukata","year":"2022","journal-title":"Anticancer Drugs"},{"key":"2024031106210578400_ref38","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ajco.13666","article-title":"Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab","volume":"18","author":"Yamamoto","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2024031106210578400_ref39","first-page":"1609","article-title":"The impact of neutrophil-to-lymphocyte ratio after two courses of pembrolizumab for oncological outcomes in patients with metastatic urothelial carcinoma","volume":"10","author":"Tomioka-Inagawa","year":"2022","journal-title":"Biomedicine"},{"key":"2024031106210578400_ref40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00262-021-03000-8","article-title":"Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR","volume":"71","author":"Kobayashi","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2024031106210578400_ref41","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1007\/s00262-022-03204-6","article-title":"Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis","volume":"71","author":"Yoshida","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2024031106210578400_ref42","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1002\/cam4.4779","article-title":"Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma","volume":"11","author":"Miyama","year":"2022","journal-title":"Cancer Med"},{"key":"2024031106210578400_ref43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3892\/ol.2022.13384","article-title":"Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma","volume":"24","author":"Teshima","year":"2022","journal-title":"Oncol Lett"},{"key":"2024031106210578400_ref44","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.urolonc.2022.02.012","article-title":"Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma","volume":"40","author":"Uchimoto","year":"2022","journal-title":"Urol Oncol"},{"key":"2024031106210578400_ref45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.21873\/cdp.10206","article-title":"Pretreatment hemoglobin levels and platelet-to-lymphocyte ratio predict survival benefit from pembrolizumab in advanced urothelial carcinoma","volume":"3","author":"Kurashina","year":"2023","journal-title":"Cancer Diagn Progn"},{"key":"2024031106210578400_ref46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00262-022-03250-0","article-title":"A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer","volume":"72","author":"Rijnders","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2024031106210578400_ref47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clgc.2022.08.004","article-title":"Site-specific differences in PD-1 blockade success and biomarkers in urothelial carcinoma treated with pembrolizumab","volume":"21","author":"Umeda","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2024031106210578400_ref48","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10147-023-02341-x","article-title":"Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab","volume":"28","author":"Nakamura","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2024031106210578400_ref49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jjco\/hyad069","article-title":"Prognostic significance of pre-treatment albumin-bilirubin grade in metastatic urothelial carcinoma receiving pembrolizumab","volume":"53","author":"Yamashita","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"2024031106210578400_ref50","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/CAD.0000000000000982","article-title":"Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report","volume":"31","author":"Fukushima","year":"2020","journal-title":"Anticancer Drugs"},{"key":"2024031106210578400_ref51","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.2147\/CMAR.S333823","article-title":"The association of clinical outcomes with posttreatment changes in the relative eosinophil counts and neutrophil-to-eosinophil ratio in patients with advanced urothelial carcinoma treated with Pembrolizumab","volume":"13","author":"Furubayashi","year":"2021","journal-title":"Cancer Manag Res"},{"key":"2024031106210578400_ref52","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.21873\/invivo.12565","article-title":"Modified Glasgow prognostic score 2 as a prognostic marker in patients with metastatic urothelial carcinoma","volume":"35","author":"Nagai","year":"2021","journal-title":"In Vivo"},{"key":"2024031106210578400_ref53","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.21873\/invivo.12659","article-title":"Impact of C-reactive protein flare response in patients with advanced urothelial carcinoma who received pembrolizumab","volume":"35","author":"Tomisaki","year":"2021","journal-title":"Vivo"},{"key":"2024031106210578400_ref54","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.3390\/cancers14205075","article-title":"Controlling nutritional status (CONUT) score and sarcopenia as mutually independent prognostic biomarkers in advanced urothelial carcinoma","volume":"14","author":"Une","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024031106210578400_ref55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/ol.2022.13635","article-title":"Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma","volume":"25","author":"Kageyama","year":"2022","journal-title":"Oncol Lett"},{"key":"2024031106210578400_ref56","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.amjsurg.2013.03.007","article-title":"Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients","volume":"206","author":"Azab","year":"2013","journal-title":"Am J Surg"},{"key":"2024031106210578400_ref57","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00384-013-1748-z","article-title":"The value of the pretreatment albumin\/globulin ratio in predicting the long-term survival in colorectal cancer","volume":"28","author":"Azab","year":"2013","journal-title":"Int J Colorectal Dis"},{"key":"2024031106210578400_ref58","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/iju.13767","article-title":"Prognostic role of the preoperative serum albumin : globulin ratio after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"25","author":"Otsuka","year":"2018","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12894-020-00700-8","article-title":"Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma","volume":"20","author":"Omura","year":"2020","journal-title":"BMC Urol"},{"key":"2024031106210578400_ref60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"2024031106210578400_ref61","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"2024031106210578400_ref62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clgc.2015.07.015","article-title":"Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma","volume":"14","author":"Taguchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"2024031106210578400_ref63","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2217\/fon-2020-0570","article-title":"Comparison of major definitions of sarcopenia based on the skeletal muscle index in patients with urothelial carcinoma","volume":"17","author":"Taguchi","year":"2021","journal-title":"Future Oncol"},{"key":"2024031106210578400_ref64","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.annonc.2019.10.020","article-title":"Inconsistencies in currently used definitions of sarcopenia in oncology","volume":"31","author":"Taguchi","year":"2020","journal-title":"Ann Oncol"},{"key":"2024031106210578400_ref65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"IMvigor210 study group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"2024031106210578400_ref66","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line Pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024031106210578400_ref67","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.2174","article-title":"Immunotherapy in the treatment of localized genitourinary cancers","volume":"9","author":"Necchi","year":"2023","journal-title":"JAMA Oncol"},{"key":"2024031106210578400_ref68","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: Atezolizumab or Pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"2024031106210578400_ref69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41585-018-0056-3","article-title":"Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma","volume":"15","author":"Powles","year":"2018","journal-title":"Nat Rev Urol"},{"key":"2024031106210578400_ref70","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024031106210578400_ref71","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11523-018-0595-9","article-title":"Immunological correlates of response to immune checkpoint inhibitors in metastatic urothelial carcinoma","volume":"13","author":"Tzeng","year":"2018","journal-title":"Target Oncol"},{"key":"2024031106210578400_ref72","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024031106210578400_ref73","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"},{"key":"2024031106210578400_ref74","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur Urol"},{"key":"2024031106210578400_ref75","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/1878-0261.13196","article-title":"Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer","volume":"16","author":"Mendelaar","year":"2022","journal-title":"Mol Oncol"},{"key":"2024031106210578400_ref76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3892\/ol.2023.13975","article-title":"Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma","volume":"26","author":"Hamada","year":"2023","journal-title":"Oncol Lett"},{"key":"2024031106210578400_ref77","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1111\/cas.15488","article-title":"Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab","volume":"113","author":"Takahashi","year":"2022","journal-title":"Cancer Sci"},{"key":"2024031106210578400_ref78","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/cancers14020263","article-title":"IFN-gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab","volume":"14","author":"Sakatani","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024031106210578400_ref79","article-title":"Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab","volume":"79","author":"Komura","year":"2023","journal-title":"Cancer Sci"},{"key":"2024031106210578400_ref80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JU.0000000000000761","article-title":"Histological subtypes and response to PD-1\/PD-L1 blockade in advanced urothelial cancer: a retrospective study","volume":"204","author":"Miller","year":"2020","journal-title":"J Urol"},{"key":"2024031106210578400_ref81","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bju.15510","article-title":"Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis","volume":"130","author":"Kobayashi","year":"2022","journal-title":"BJU Int"},{"key":"2024031106210578400_ref82","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clgc.2022.05.001","article-title":"Efficacy of Pembrolizumab in patients with variant urothelial carcinoma: a multicenter retrospective study","volume":"20","author":"Minato","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2024031106210578400_ref83","doi-asserted-by":"crossref","first-page":"153364","DOI":"10.1016\/j.prp.2021.153364","article-title":"Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma","volume":"219","author":"Miyama","year":"2021","journal-title":"Pathol Res Pract"},{"key":"2024031106210578400_ref84","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.21873\/anticanres.15851","article-title":"Impact of histological variants on clinical responses to pembrolizumab in patients with metastatic urothelial cancer","volume":"42","author":"Inoue","year":"2022","journal-title":"Anticancer Res"},{"key":"2024031106210578400_ref85","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract Tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"2024031106210578400_ref86","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"2024031106210578400_ref87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref88","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2019.05.017","article-title":"Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients","volume":"116","author":"Kawai","year":"2019","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref89","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000505340","article-title":"Association of immune-related adverse events with pembrolizumab efficacy in the treatment of advanced urothelial carcinoma","volume":"98","author":"Kobayashi","year":"2020","journal-title":"Oncology"},{"key":"2024031106210578400_ref90","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clgc.2020.07.003","article-title":"Association between the occurrence and Spectrum of immune-related adverse events and efficacy of pembrolizumab in Asian patients with advanced urothelial cancer: Multicenter retrospective analyses and systematic literature review","volume":"19","author":"Kijima","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"2024031106210578400_ref91","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.2147\/CMAR.S360473","article-title":"Association between immune-related adverse events and efficacy and changes in the relative eosinophil count among patients with advanced urothelial carcinoma treated by Pembrolizumab","volume":"14","author":"Furubayashi","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2024031106210578400_ref92","doi-asserted-by":"crossref","first-page":"e003965","DOI":"10.1136\/jitc-2021-003965","article-title":"Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis","volume":"10","author":"Kawai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2024031106210578400_ref93","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1111\/cas.15539","article-title":"Immune-related adverse events in urothelial cancer patients: adjustment for immortal time bias","volume":"113","author":"Otsuka","year":"2022","journal-title":"Cancer Sci"},{"key":"2024031106210578400_ref94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcrc.2016.07.017","article-title":"Immortal time bias in observational studies of time-to-event outcomes","volume":"36","author":"Jones","year":"2016","journal-title":"J Crit Care"},{"key":"2024031106210578400_ref95","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"Eur Urol"},{"key":"2024031106210578400_ref96","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2024031106210578400_ref97","doi-asserted-by":"crossref","first-page":"100090","DOI":"10.1016\/j.esmoop.2021.100090","article-title":"Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study","volume":"6","author":"Ruiz-Ba\u00f1obre","year":"2021","journal-title":"ESMO Open"},{"key":"2024031106210578400_ref98","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.urolonc.2021.05.033","article-title":"Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma","volume":"39","author":"Ishiyama","year":"2021","journal-title":"Urol Oncol"},{"key":"2024031106210578400_ref99","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1248\/bpb.b21-00939","article-title":"Effects of proton pump inhibitors on survival outcomes in patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab","volume":"45","author":"Kunimitsu","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"2024031106210578400_ref100","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.21873\/anticanres.15638","article-title":"Impact of the use of proton pump inhibitors on pembrolizumab effectiveness for advanced urothelial carcinoma","volume":"42","author":"Tomisaki","year":"2022","journal-title":"Anticancer Res"},{"key":"2024031106210578400_ref101","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/bco2.118","article-title":"Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma","volume":"3","author":"Okuyama","year":"2021","journal-title":"BJUI Compass"},{"key":"2024031106210578400_ref102","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2022.02.020","article-title":"Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors","volume":"40","author":"Fukuokaya","year":"2022","journal-title":"Urol Oncol"},{"key":"2024031106210578400_ref103","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/iju.15151","article-title":"Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab","volume":"30","author":"Tomisaki","year":"2023","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref104","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","article-title":"Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index","volume":"142","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2021.03.041","article-title":"Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy","volume":"150","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref106","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2022.06.002","article-title":"Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade","volume":"172","author":"Takada","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref107","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CJI.0000000000000446","article-title":"Concomitant drugs prognostic score in patients with metastatic renal cell carcinoma receiving ipilimumab and nivolumab in the compassionate use program in Italy: brief communication","volume":"46","author":"Buti","year":"2023","journal-title":"J Immunother"},{"key":"2024031106210578400_ref108","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2217\/imt-2023-0028","article-title":"Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab","volume":"15","author":"Taguchi","year":"2023","journal-title":"Immunotherapy"},{"key":"2024031106210578400_ref109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"2024031106210578400_ref110","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science"},{"key":"2024031106210578400_ref111","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"2024031106210578400_ref112","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","article-title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","volume":"28","author":"Dizman","year":"2022","journal-title":"Nat Med"},{"key":"2024031106210578400_ref113","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2024031106210578400_ref114","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur Urol Focus"},{"key":"2024031106210578400_ref115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"2024031106210578400_ref116","doi-asserted-by":"crossref","first-page":"103241","DOI":"10.1016\/j.critrevonc.2021.103241","article-title":"Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"159","author":"Bersanelli","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024031106210578400_ref117","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"2024031106210578400_ref118","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/ajco.13765","article-title":"Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region","volume":"18","author":"Eto","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2024031106210578400_ref119","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/iju.15231","article-title":"The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion","volume":"30","author":"Hara","year":"2023","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref120","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"},{"key":"2024031106210578400_ref121","doi-asserted-by":"crossref","first-page":"8355","DOI":"10.1002\/cam4.3445","article-title":"Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: a preliminary study","volume":"9","author":"Fukushima","year":"2020","journal-title":"Cancer Med"},{"key":"2024031106210578400_ref122","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/ijms22020535","article-title":"Combination of cisplatin and irradiation induces immunogenic cell death and potentiates postirradiation anti-PD-1 treatment efficacy in urothelial carcinoma","volume":"22","author":"Fukushima","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024031106210578400_ref123","first-page":"100558","article-title":"Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival","volume":"39","author":"Nakamori","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"2024031106210578400_ref124","doi-asserted-by":"crossref","first-page":"e003868","DOI":"10.1136\/jitc-2021-003868","article-title":"Efficacy of pembrolizumab and comprehensive CD274\/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer","volume":"10","author":"Nishimura","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2024031106210578400_ref125","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.21873\/anticanres.16373","article-title":"Efficacy and tolerability of second-line Pembrolizumab with radiation therapy in advanced urothelial carcinoma","volume":"43","author":"Sano","year":"2023","journal-title":"Anticancer Res"},{"key":"2024031106210578400_ref126","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"key":"2024031106210578400_ref127","doi-asserted-by":"crossref","first-page":"117955492110216","DOI":"10.1177\/11795549211021667","article-title":"Clinical outcomes of patients with metastatic urothelial carcinoma after progression to immune checkpoint inhibitors: a retrospective analysis by the meet-URO group (meet-URO 1 study)","volume":"15","author":"Bersanelli","year":"2021","journal-title":"Clin Med Insights Oncol"},{"key":"2024031106210578400_ref128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00262-021-02980-x","article-title":"Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma","volume":"71","author":"Fukuokaya","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2024031106210578400_ref129","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/iju.14861","article-title":"Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era","volume":"29","author":"Kita","year":"2022","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bju.15893","article-title":"Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma","volume":"131","author":"Uchimoto","year":"2023","journal-title":"BJU Int"},{"key":"2024031106210578400_ref131","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ccell.2023.08.004","article-title":"Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression","volume":"41","author":"Topp","year":"2023","journal-title":"Cancer Cell"},{"key":"2024031106210578400_ref132","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024031106210578400_ref133","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/cam4.5057","article-title":"Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study","volume":"12","author":"Ito","year":"2023","journal-title":"Cancer Med"},{"key":"2024031106210578400_ref134","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2018.09.002","article-title":"Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen","volume":"104","author":"Gravis","year":"2018","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.eururo.2017.08.022","article-title":"Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer","volume":"73","author":"Szabados","year":"2018","journal-title":"Eur Urol"},{"key":"2024031106210578400_ref136","first-page":"455","article-title":"Organ-specific therapeutic effect of paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma","volume":"12","author":"Furubayashi","year":"2020","journal-title":"Res Rep Urol"},{"key":"2024031106210578400_ref137","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.21873\/anticanres.15393","article-title":"Response to platinum-based chemotherapy rechallenge for patients with pembrolizumab-refractory urothelial carcinoma","volume":"41","author":"Yumioka","year":"2021","journal-title":"Anticancer Res"},{"key":"2024031106210578400_ref138","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euo.2019.03.001","article-title":"Single-centre experience of patients with metastatic urothelial cancer treated with chemotherapy following immune checkpoint inhibition","volume":"4","author":"Lam","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2024031106210578400_ref139","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2022.08.014","article-title":"Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma","volume":"175","author":"Meynard","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref140","doi-asserted-by":"crossref","DOI":"10.1111\/iju.15300","article-title":"Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study","volume":"30","author":"Taguchi","year":"2023","journal-title":"Int J Urol"},{"key":"2024031106210578400_ref141","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2018.06.005","article-title":"Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression","volume":"101","author":"Bernard-Tessier","year":"2018","journal-title":"Eur J Cancer"},{"key":"2024031106210578400_ref142","doi-asserted-by":"crossref","first-page":"e002850","DOI":"10.1136\/jitc-2021-002850","article-title":"Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events","volume":"9","author":"Siddiqui","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2024031106210578400_ref143","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/iju5.12474","article-title":"Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma","volume":"5","author":"Nishimura","year":"2022","journal-title":"IJU Case Rep"},{"key":"2024031106210578400_ref144","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clgc.2022.11.003","article-title":"Treatment Rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma","volume":"21","author":"Makrakis","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2024031106210578400_ref145","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0022-5347(05)66533-0","article-title":"Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer","volume":"165","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"2024031106210578400_ref146","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.eururo.2008.11.039","article-title":"Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30\/05)","volume":"55","author":"Lehmann","year":"2009","journal-title":"Eur Urol"},{"key":"2024031106210578400_ref147","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.eururo.2008.12.011","article-title":"Is metastasectomy for urothelial carcinoma worthwhile?","volume":"55","author":"Herr","year":"2009","journal-title":"Eur Urol"},{"key":"2024031106210578400_ref148","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","article-title":"Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan","volume":"191","author":"Abe","year":"2014","journal-title":"J Urol"},{"key":"2024031106210578400_ref149","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1245\/s10434-017-5970-8","article-title":"Oncologic outcome of Metastasectomy for urothelial carcinoma: who is the best candidate?","volume":"24","author":"Nakagawa","year":"2017","journal-title":"Ann Surg Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/3\/254\/56912449\/hyad172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/3\/254\/56912449\/hyad172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:26:37Z","timestamp":1710138397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/3\/254\/7477295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":149,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,18]]},"published-print":{"date-parts":[[2024,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad172","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,12,18]]}}}